Feedback
Settings

Settings

Goto Application

1. WO2020157498 - TREATMENT OF NEUROTOXICITY AND / OR CYTOKINE RELEASE SYNDROME

PermaLink
Publication Number WO/2020/157498
Publication Date 06.08.2020
International Application No. PCT/GB2020/050208
International Filing Date 29.01.2020
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/725 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
CPC
A61K 38/2006
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2006IL-1
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 14/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
Applicants
  • AUTOLUS LIMITED [GB]/[GB]
Inventors
  • PEDDAREDDIGARI, Vijay
Agents
  • D YOUNG & CO LLP
Priority Data
1901187.329.01.2019GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF NEUROTOXICITY AND / OR CYTOKINE RELEASE SYNDROME
(FR) TRAITEMENT DE LA NEUROTOXICITÉ ET/OU DU SYNDROME DE LIBÉRATION DE CYTOKINES
Abstract
(EN) The present invention relates to the use of an IL-1β inhibitor for the prevention and/or treatment of neurotoxicity and/or cytokine release syndrome in a subject undergoing immunotherapy, wherein the IL-1β inhibitor is administered before immunotherapy.
(FR) La présente invention concerne l'utilisation d'un inhibiteur d'IL-1β pour la prévention et/ou le traitement de la neurotoxicité et/ou du syndrome de libération de cytokines chez un sujet suivant une immunothérapie, l'inhibiteur d'IL-1β étant administré avant l'immunothérapie.
Related patent documents
EP3917958
US20220089724
Latest bibliographic data on file with the International Bureau
# -